<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2436">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05175664</url>
  </required_header>
  <id_info>
    <org_study_id>H-21040317</org_study_id>
    <nct_id>NCT05175664</nct_id>
  </id_info>
  <brief_title>Novel Diagnostic and Disease Stage Biomarkers in AD</brief_title>
  <acronym>TRACK-AD</acronym>
  <official_title>TRacking AlzheimerÂ´s Disease: a Study of Disease trajeCtory and Development of Diagnostic and Disease Stage biomarKers in AD (TRACK-AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Dementia Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Dementia Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy of novel biomarkers, namely blood-based biomarkers,&#xD;
      pupillometry and actigraphy to track and predict progression of Alzheimer's disease (AD).&#xD;
      Furthermore, the study will investigate the diagnostic value of pupillometry and actigraphy&#xD;
      for AD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consist of three sub-studies.&#xD;
&#xD;
      In study 1, participants diagnosed with mild cognitive impairment due to AD or mild to&#xD;
      moderate AD will be followed for up to 24 months with repeated blood samples, pupillometry,&#xD;
      actigraphy, cognitive tests and a control brain scan.&#xD;
&#xD;
      In study 2, patients under investigation of a neurodegenerative disease who have a planned&#xD;
      lumbar puncture in the Memory clinic will be invited to this study. Participants will undergo&#xD;
      pupillometry and blood samples two times approximately one and four weeks after the lumbar&#xD;
      puncture.&#xD;
&#xD;
      In study 3, participants with a dementia diagnosis will undergo pupillometry and actigraphy&#xD;
      at a single visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in CDR</measure>
    <time_frame>Two years</time_frame>
    <description>Clinical Dementia Rating (CDR), a clinical tool for grading the relative severity of dementia with scores ranging from 0 (no impairment) to 3 (severe impairment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MMSE</measure>
    <time_frame>Two years</time_frame>
    <description>Mini Mental Status Examination (MMSE), used to test global cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MR brain scan</measure>
    <time_frame>12 months</time_frame>
    <description>Magnetic Resonance Imaging (MR), used to asses changes in volumetric measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FDG-PET brain scan</measure>
    <time_frame>12 months</time_frame>
    <description>Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) of the brain, used to asses changes in brain metabolism</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Neuro-Degenerative Diseases</condition>
  <condition>Vascular Dementia</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>MCI</arm_group_label>
    <description>Patients suffering from mild cognitive impairment (MCI) due to Alzheimer's disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD</arm_group_label>
    <description>Patients diagnosed with mild to moderate Alzheimer's disease (AD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NDD</arm_group_label>
    <description>Patients under investigation of a neurodegenerative disease (NDD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DLB</arm_group_label>
    <description>Patients diagnosed with Dementia with Lewy Bodies (DLB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VaD</arm_group_label>
    <description>Patients with vascular dementia (VaD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTD</arm_group_label>
    <description>Frontotemporal dementia (FTD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH</arm_group_label>
    <description>Normal pressure hydrocephalus (NPH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy Controls without brain disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Long-term study</intervention_name>
    <description>No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.</description>
    <arm_group_label>AD</arm_group_label>
    <arm_group_label>MCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Short-term study</intervention_name>
    <description>No intervention. Investigations: blood samples and pupillometry.</description>
    <arm_group_label>NDD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cross-sectional study</intervention_name>
    <description>No intervention. Investigations: cognitive tests, pupillometry and actigraphy.</description>
    <arm_group_label>AD</arm_group_label>
    <arm_group_label>DLB</arm_group_label>
    <arm_group_label>FTD</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>NPH</arm_group_label>
    <arm_group_label>VaD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood: A total of 12 mL of blood will be collected at the study visits. Afterwards, the blood&#xD;
      will be centrifuged and the serum, plasma and the white blood cells will be extracted. These&#xD;
      samples will be stored in the Danish Dementia Biobank prior to analyses.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In the longitudinal study (1) the investigators will include 100 patients diagnosed with&#xD;
        mild cognitive impairment due to Alzheimer's disease or diagnosed with mild to moderate&#xD;
        Alzheimer's disease. In the short-term study (2) the investigators will include 40 patients&#xD;
        who are under investigation of a neurodegenerative disease. In the cross-sectional study&#xD;
        (3) the investigatorswill include 50 patients with Alzheimer's disease, 50 healthy controls&#xD;
        without brain disease, and 100 patients with other forms of dementia (dementia with Lewy&#xD;
        body, vascular dementia, normal pressure hydrocephalus, frontotemporal dementia).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Longitudinal study:&#xD;
&#xD;
             Inclusion criteria:&#xD;
&#xD;
               -  MCI due to AD, or mild or moderate AD dementia according to the National&#xD;
                  Institute on Aging and Alzheimer's Association (NIA-AA) diagnostic criteria&#xD;
&#xD;
               -  Caregiver willing to participate as an informant&#xD;
&#xD;
               -  MMSE &gt;19 at inclusion&#xD;
&#xD;
               -  Brain FDG-PET/MRI or FDG/PET-CT&#xD;
&#xD;
               -  Able to cooperate to the investigations and give informed consent&#xD;
&#xD;
             Exclusion criteria:&#xD;
&#xD;
               -  Other neurological or psychiatric illness that may affect neurofilament light&#xD;
                  (NfL) levels (severe neuropathy, multiple sclerosis (MS), stroke within the last&#xD;
                  3 months, Wernicke encephalopathy)&#xD;
&#xD;
               -  Diagnosis of previous or current major psychiatric disorder (schizophrenia,&#xD;
                  bipolar disorder, psychosis) within last 2 years&#xD;
&#xD;
               -  Excessive alcohol intake or substance abuse within the last 2 years&#xD;
&#xD;
               -  Ophthalmological disorders that may affect pupillometry&#xD;
&#xD;
               -  Participating in drug trials or other intervention trials&#xD;
&#xD;
          2. Short-term study:&#xD;
&#xD;
             Inclusion criteria:&#xD;
&#xD;
               -  Patients under investigation of a neurodegenerative disease&#xD;
&#xD;
               -  MMSE &gt;19&#xD;
&#xD;
               -  Scheduled lumbar puncture/lumbar puncture performed within the last week prior to&#xD;
                  inclusion&#xD;
&#xD;
               -  Written consent form to the Danish Dementia Biobank&#xD;
&#xD;
               -  Able to cooperate to the investigations&#xD;
&#xD;
             Exclusion criteria:&#xD;
&#xD;
               -  Other neurological or psychiatric illness that may affect NfL levels (severe&#xD;
                  neuropathy, MS, stroke within the last 3 months, Wernicke encephalopathy)&#xD;
&#xD;
               -  Excessive alcohol intake or substance abuse within the last 2 years&#xD;
&#xD;
               -  Ophthalmological disorders that may affect pupillometry&#xD;
&#xD;
               -  Participating in drug trials or other intervention trials&#xD;
&#xD;
          3. Cross-sectional study:&#xD;
&#xD;
        Inclusion criteria - Patients:&#xD;
&#xD;
          -  A diagnosis of a dementia disorder&#xD;
&#xD;
          -  Caregiver willing to participate as an informant&#xD;
&#xD;
          -  MMSE &gt;15 at inclusion&#xD;
&#xD;
          -  Able to cooperate to the investigations&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion criteria - Patients:&#xD;
&#xD;
          -  Diagnosis of previous or current major psychiatric disorder (schizophrenia, bipolar&#xD;
             disorder, psychosis) within last 2 years&#xD;
&#xD;
          -  Excessive alcohol intake or substance abuse within the last 2 years&#xD;
&#xD;
          -  Other known brain disorder&#xD;
&#xD;
          -  Ophthalmological disorders that may affect pupillometry&#xD;
&#xD;
          -  Participating in drug trials or other intervention trials&#xD;
&#xD;
        Inclusion criteria - Healthy Controls:&#xD;
&#xD;
          -  Able to cooperate to the investigations&#xD;
&#xD;
          -  Normal cognition&#xD;
&#xD;
          -  Age 50-90 year&#xD;
&#xD;
        Exclusion criteria - Healthy Controls:&#xD;
&#xD;
          -  Diagnosis of previous or current major psychiatric disorder (schizophrenia, bipolar&#xD;
             disorder, psychosis) within last 2 years&#xD;
&#xD;
          -  Excessive alcohol intake or substance abuse within the last 2 years&#xD;
&#xD;
          -  Other known brain disorder&#xD;
&#xD;
          -  Ophthalmological disorders that may affect pupillometry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederikke Kragh Clemmensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathias Holsey Gramkow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian Steen Frederiksen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steen Gregers Hasselbalch, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anja Hviid Simonsen, MSc Pharm PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristian Steen Frederiksen, MD, PhD</last_name>
    <phone>+45 35 45 69 22</phone>
    <email>kristian.steen.frederiksen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steen Gregers Hasselbalch, DMSc</last_name>
    <phone>+45 35 45 69 22</phone>
    <email>steen.gregers.hasselbalch@regionh.dk</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>January 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2022</study_first_posted>
  <last_update_submitted>January 3, 2022</last_update_submitted>
  <last_update_submitted_qc>January 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Pupillometry</keyword>
  <keyword>Actigraphy</keyword>
  <keyword>Blood-based biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

